- MannKind press release ( NASDAQ: MNKD ): Q2 GAAP EPS of -$0.11 misses by $0.02 .
- Revenue of $18.89M (-18.9% Y/Y) beats by $3.27M .
- Afrezza gross profit for the second quarter of 2022 was $7.3 million compared to $5.6 million in the same period of 2021, an increase of $1.7 million, or 31%, which was driven by an increase in Afrezza sales and a decrease in cost of goods sold.
- Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere ® inhalation platform
- V-Go ® acquired May 31; $2.1 million Net Revenue recognized for June.
- 2Q 2022 Collaboration and Services Revenue of $5.9 million; +171% vs. 1Q 2022.
For further details see:
MannKind GAAP EPS of -$0.11 misses by $0.02, revenue of $18.89M beats by $3.27M